HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court Slays POM Wonderful's Appeal Of FTC Order

This article was originally published in The Tan Sheet

Executive Summary

The high court denies the firm's writ of certiorari to review an appellate 2015 ruling largely upholding a 2013 FTC order on claims made for POM Wonderful 100% Pomegranate Juice and POMx pills and liquid supplements.

You may also be interested in...



HBW US Executive Decisions: Engle Leaves FTC, Changes At Nature's Bounty, CRN And Benev

Mary Engle led FTC enforcement actions including against POM Wonderful’s claims for its pomegranate supplements; Huber is CRN’s scientific and regulatory affairs VP and Amanda Darlington is government relations director; Jones takes charge of Nature’s Bounty supply chain; and Benev Co. names five aesthetic experts to Medical Advisory Board to advance its “medically developed cosmeceutical line.”

Health, Beauty And Wellness News: POM Wonderful On 'Health Scare' Swim In Ad

Online, pamphlet claims trip Baker's Best; MusclePharm maintains turnaround progress; Kameka enters probiotic market through AB-Biotics; and POM Wonderful ad swims on humor.

Sweeping Change At FTC May Sweep Away RCT Standard For Health Claims

Confirmations by the Senate mark FTC ’s first-ever complete leadership turnover at once and fill out the roster for the first time since President Trump’s election in 2016. The agency has been operating with two commissioners since soon after the election.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI964826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel